N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
• Collaborator: Conselho Nacional de Desenvolvimento Científico e Tecnológico
• Treatments: Acetylcysteine; Deferoxamine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Patients admitted to the ICU

• Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion

Exclusion Criteria:

• Age lower than 18 years old

• Chronic renal failure

• A known history of allergy to any of the study drugs

• Using n-acetylcysteine to paracetamol overdose

• Pregnant women

• Patients who used iodinated contrast medium

• Hemoglobin less than 6.5 mg/dl

• Cancer patients